Lim Li-Anne, Madigan Michele C, Conway R Max
Save Sight Institute, Clinical Ophthalmology, The University of Sydney, Sydney, New South Wales, Australia.
Clin Ophthalmol. 2013;6:521-31. doi: 10.2147/OPTH.S38415. Epub 2013 Mar 13.
The aim of this study was to review the available literature and identify recent advances in the classification and management of conjunctival melanoma (CM) for clinicians working in this field. English-based articles were identified using the MEDLINE(®) database, and additional cited works not detected in the initial search were also obtained. Articles were assessed according to the Australian National Health and Medical Research Council levels of evidence criteria. Review of the literature indicated that the current classification and management of CM is predominantly based upon primarily nonrandomized, single-institution, retrospective case series. While these studies provide the basis for the recent seventh edition of the tumor node metastasis staging classification, this classification more accurately reflects the current knowledge of prognostic factors for CM. Application of this revised classification system together with prospective trials will provide the opportunity for future consistent and comparable data collection across centers, and it will improve the quality of evidence upon which current classification and management of CM is based. Furthermore, the high risk of local recurrence with current standard management suggests that adjuvant therapy, particularly mitomycin C and/or brachytherapy, may improve outcomes regardless of clinical staging. Finally, the use of sentinel lymph node biopsy may have significant benefit for a select group of CM patients.
本研究的目的是为该领域的临床医生回顾现有文献,并确定结膜黑色素瘤(CM)在分类和管理方面的最新进展。使用MEDLINE®数据库检索以英文发表的文章,并获取在初始检索中未发现的其他被引用文献。根据澳大利亚国家卫生与医学研究委员会的证据水平标准对文章进行评估。文献综述表明,目前CM的分类和管理主要基于非随机、单机构、回顾性病例系列研究。虽然这些研究为最近的第七版肿瘤淋巴结转移分期分类提供了基础,但该分类更准确地反映了目前关于CM预后因素的知识。应用这一修订后的分类系统并开展前瞻性试验,将为未来各中心进行一致且可比的数据收集提供机会,并将提高目前CM分类和管理所依据的证据质量。此外,当前标准治疗存在较高的局部复发风险,这表明辅助治疗,尤其是丝裂霉素C和/或近距离放疗,无论临床分期如何,都可能改善治疗效果。最后,前哨淋巴结活检的应用可能对特定组别的CM患者有显著益处。